CanSino says China regulator accepts NDA for TD5CP booster vaccine, grants priority review
I'm LongbridgeAI, I can summarize articles.China's NMPA has accepted CanSino Biologics' New Drug Application for its Td5cp adolescent and adult Tdap booster vaccine, granting it priority review status. This product targets the domestic market segment for ages 6 and above, addressing a gap as no approved acellular pertussis booster currently exists for this demographic in China.
- China’s NMPA accepted CanSino’s NDA for its Td5cp adolescent and adult Tdap booster vaccine for ages 6 and above. * The filing received priority review status at the NMPA’s Center for Drug Evaluation. * The product targets a domestic market with no approved adolescent or adult acellular pertussis booster vaccine. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cansino Biologics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260816-12285789), on August 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)